In the past few months, we have seen how substandard and falsified (SF) medical products undermine the COVID-19 response. Supply chain disruptions and urgent demand have increased the risk of poor-quality medicines and unproven cures, highlighting an unprecedented need for regulators to ensure timely access to safe and effective quality medical products.
It is increasingly clear that to end the COVID-19 pandemic, we must guarantee timely and equitable access to quality medicines. To meet this goal, we need resilient pharmaceutical supply chains backed by strong regulatory systems to ensure the safety of future COVID-19 drugs and to limit the spread of substandard and falsified medical products.
When we started this coalition in 2018, we knew quality and trust were at the center of every health system and the key to achieving our collective health goals. However, we could not have predicted what these two years would look like. Our work is far from over.
Today, patients in the United States and around the world depend on medicines—and the ingredients used to make those medicines—sourced from and manufactured around the globe. This global supply chain for medicines, while providing some inherent risk mitigation, has numerous vulnerabilities that can be challenged by acute disruptions. When such a disruption occurs, concerns arise regarding the quality and safety—as well as shortages—of medicines, particularly those used for critical treatments. Unfortunately, the COVID-19 pandemic brought these impacts into sharp focus.
Declaración de Oxford y su llamado a la acción para acceso global a productos médicos de calidad garantizada
Los productos médicos de calidad inferior y falsificados (especialmente los medicamentos, las vacunas, los productos biológicos y los diagnósticos) (1) representan una amenaza significativa y creciente para la salud humana. Los medicamentos y productos médicos de calidad inferior son el resultado de errores, corrupción, negligencia o malas prácticas de fabricación, adquisición, regulación, transporte o almacenaje. En cambio, los productos falsificados son el resultado de un fraude criminal.
We are living in unprecedented times. As COVID-19 continues to spread, the pandemic has exposed gaps in the global pharmaceutical supply chain and has stretched national health systems thin. Around the world, reports of falsified medicines and unproven treatments are circulating. Now, more than ever, we must raise our collective to voice to call for safe, quality care for everyone, everywhere.
An Arizona man is dead and his wife was hospitalized after the couple ingested a form of chloroquine, a chemical that has been hailed recently by President Trump as a possible "game changer" in the fight against the novel coronavirus, according to the Phoenix hospital that treated the couple.
The spread of coronavirus (COVID-19) has turned into a global pandemic with alarming speed, prompting many to have questions about the stability of global medical product supply chains. Many low- and middle-income countries may face greater risk of medical product shortages as a result of COVID-19, and the pandemic may also exacerbate the ongoing problem of substandard and falsified medicines.
We hope you had a restful holiday season and are settling into the new year! Coming off the heels of a successful 2019, we’re excited to make 2020 the Medicines We Can Trust campaign’s most ambitious year yet.